The Bevacizumab Experience in Advanced Renal Cell Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2010 Nov 5

PMID 21049084

Citations 8

Authors

Lauren C Harshman

Sandy Srinivas

Affiliations

Soon will be listed here.

Abstract

Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9-10 months are comparable to the other approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages include a different toxicity profile and assurance of administration compliance given its intravenous formulation. Enthusiasm for its use is blunted by the increased costs, the potential infusion-related reactions, the associated interferon-related toxicities, and the inconvenience of its nonoral formulation. Further study is warranted to assess its efficacy both as a single agent and in combination with the targeted agents and other immunotherapies. With multiple agents now available for the treatment of advanced RCC, identification of patient and tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence of subsequent therapies is imperative.

Citing Articles

Knockdown of Antisense Noncoding Mitochondrial RNA Reduces Tumorigenicity of Patient-Derived Clear Cell Renal Carcinoma Cells in an Orthotopic Xenograft Mouse Model.

Araya M, Sepulveda F, Villegas J, Alarcon L, Burzio L, Burzio V Cancers (Basel). 2024; 16(4).

PMID: 38398221 PMC: 10886546. DOI: 10.3390/cancers16040830.

Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.

Jeon H, Byun J, Kang H, Kim K, Lee E, Kim J J Transl Med. 2023; 21(1):69.

PMID: 36732815 PMC: 9893563. DOI: 10.1186/s12967-023-03936-8.

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.

Jain S, Chalif E, Aghi M Front Oncol. 2022; 11:812916.

PMID: 35096619 PMC: 8790087. DOI: 10.3389/fonc.2021.812916.

Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs.

Montemagno C, Pages G Front Cell Dev Biol. 2020; 8:584.

PMID: 32775327 PMC: 7381352. DOI: 10.3389/fcell.2020.00584.

Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.

Kamli H, Li L, Gobe G Ochsner J. 2019; 19(2):138-151.

PMID: 31258426 PMC: 6584192. DOI: 10.31486/toj.18.0015.

References

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. View

Dudek A, Zolnierek J, Dham A, Lindgren B, Szczylik C . Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2008; 115(1):61-7. DOI: 10.1002/cncr.24009. View

Hainsworth J, Sosman J, Spigel D, Edwards D, Baughman C, Greco A . Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005; 23(31):7889-96. DOI: 10.1200/JCO.2005.01.8234. View

Jonasch E, Wood C, Matin S, Tu S, Pagliaro L, Corn P . Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(25):4076-81. PMC: 4371138. DOI: 10.1200/JCO.2008.21.3660. View

Telli M, Witteles R, Fisher G, Srinivas S . Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008; 19(9):1613-8. DOI: 10.1093/annonc/mdn168. View

Motzer R, Bacik J, Murphy B, Russo P, Mazumdar M . Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20(1):289-96. DOI: 10.1200/JCO.2002.20.1.289. View

Eichelberg C, Heuer R, Chun F, Hinrichs K, Zacharias M, Huland H . Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008; 54(6):1373-8. DOI: 10.1016/j.eururo.2008.07.051. View

Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C . Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2008; 20(2):227-30. DOI: 10.1093/annonc/mdn637. View

10.

Choueiri T, Schutz F, Je Y, Rosenberg J, Bellmunt J . Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010; 28(13):2280-5. DOI: 10.1200/JCO.2009.27.2757. View

11.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C . Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605):2103-11. DOI: 10.1016/S0140-6736(07)61904-7. View

12.

Bukowski R, Kabbinavar F, Figlin R, Flaherty K, Srinivas S, Vaishampayan U . Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007; 25(29):4536-41. DOI: 10.1200/JCO.2007.11.5154. View

13.

Lonser R, Glenn G, Walther M, Chew E, Libutti S, Linehan W . von Hippel-Lindau disease. Lancet. 2003; 361(9374):2059-67. DOI: 10.1016/S0140-6736(03)13643-4. View

14.

DAmato R, Loughnan M, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91(9):4082-5. PMC: 43727. DOI: 10.1073/pnas.91.9.4082. View

15.

Latif F, Tory K, Gnarra J, Yao M, Duh F, Orcutt M . Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993; 260(5112):1317-20. DOI: 10.1126/science.8493574. View

16.

Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C . First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008; 19(8):1470-1476. DOI: 10.1093/annonc/mdn161. View

17.

Cowey C, Amin C, Pruthi R, Wallen E, Nielsen M, Grigson G . Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010; 28(9):1502-7. PMC: 4525128. DOI: 10.1200/JCO.2009.24.7759. View

18.

Rini B, Michaelson M, Rosenberg J, Bukowski R, Sosman J, Stadler W . Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008; 26(22):3743-8. DOI: 10.1200/JCO.2007.15.5416. View

19.

Yang J . Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004; 10(18 Pt 2):6367S-70S. DOI: 10.1158/1078-0432.CCR-050006. View

20.

Zimmermann K, Schmittel A, Steiner U, Asemissen A, Knoedler M, Thiel E . Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2009; 76(5):350-4. DOI: 10.1159/000209961. View